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Biolimus-eluting biodegradable polymer-coated stent versus 
durable polymer-coated sirolimus-eluting stent in unselected 
patients receiving percutaneous coronary intervention 
(SORT OUT V): a randomised non-inferiority trial
Evald Høj Christiansen, Lisette Okkels Jensen, Per Thayssen, Hans-Henrik Tilsted, Lars Romer Krusell, Knud Nørregaard Hansen, Anne Kaltoft, 
Michael Maeng, Steen Dalby Kristensen, Hans Erik Bøtker, Christian Juhl Terkelsen, Anton Boel Villadsen, Jan Ravkilde, Jens Aarøe, Morten Madsen, 
Leif Thuesen, Jens Flensted Lassen, for the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) V investigators
Summary
Background Third-generation biodegradable polymer drug-eluting stents might reduce the risk of stent thrombosis 
compared with fi rst-generation permanent polymer drug-eluting stents. We aimed to further investigate the eff ects of 
a biodegradable polymer biolimus-eluting stent compared with a durable polymer-coated sirolimus-eluting stent in a 
population-based setting.
Methods This randomised, multicentre, all-comer, non-inferiority trial was undertaken at three sites across western 
Denmark. Eligible patients were aged 18 years or older with chronic stable coronary artery disease or acute coronary 
syndromes, and at least one coronary artery lesion (>50% diameter stenosis). We randomly assigned patients (1:1) using 
an independently managed computer-generated allocation sequence to receive either a biolimus-eluting biodegradable 
polymer stent (Nobori, Terumo, Tokyo, Japan) or a sirolimus-eluting permanent polymer stent (Cypher Select Plus, 
Cordis, Johnson & Johnson, Warren, NJ, USA). The primary endpoint was a composite of safety (cardiac death, 
myocardial infarction, defi nite stent thrombosis) and effi  cacy (target vessel revascularisation) at 9 months, analysed by 
intention to treat (non-inferiority margin of 0·02). This trial is registered with ClinicalTrials.gov, number NCT01254981.
Findings From July, 2009, to January, 2011, we assigned 1229 patients (1532 lesions) to receive the biolimus-eluting 
stent and 1239 (1555 lesions) to receive the sirolimus-eluting stent. One patient was lost to follow-up because of 
emigration. Intention-to-treat analysis showed that 50 (4·1%) patients who were assigned the biolimus-eluting stent 
and 39 (3·1%) who were assigned the sirolimus-eluting stent met the primary endpoint (risk diff erence 0·9% [upper 
limit of one-sided 95% CI 2·1%]; pnon-inferiority=0·06). Signifi cantly more patients in the biolimus-eluting stent group had 
defi nite stent thrombosis at 12 months than did those in the sirolimus-eluting stent group (9 [0·7%] vs 2 [0·2%], risk 
diff erence 0·6% [95% CI 0·0–1·1]; p=0·034). Per-protocol analysis showed that 45 (3·8%) of 1193 patients who 
received a biolimus-eluting stent and 39 (3·2%) of 1208 who received a sirolimus-eluting stent met the primary 
endpoint (risk diff erence 0·5% [upper limit of one-sided 95% CI 1·8%]; pnon-inferiority=0·03). 
Interpretation At 1 year follow-up, the biodegradable polymer biolimus-eluting Nobori stent did not improve clinical 
results compared with a fi rst-generation sirolimus-eluting stent. We will need to obtain long-term data before we can 
make recommendations for the role of this biolimus-eluting stent in routine clinical practice.
Funding Terumo and Cordis (Johnson & Johnson).
Introduction
By controlling the release of antiproliferative drugs from 
a polymer surface, fi rst-generation drug-eluting stents 
(DES) reduce the risk of restenosis and the need for 
repeat revascularisation compared with bare-metal 
stents,1–3 but at the expense of an increased risk of very 
late (>1 year) stent thrombosis.4,5 Incomplete endothe-
lialisation of the stent struts and positive vessel 
remodelling due to chronic infl ammation might cause 
this thrombosis, because the persistence of polymer 
material on fi rst-generation DES after completed drug 
release might trigger an infl ammatory response.6,7 
Biodegradable polymer DES aim to overcome this 
problem by providing similar controlled drug release 
with subsequent degradation of the polymer. Umirolimus 
(commonly known as biolimus)-eluting stents were 
designed with a bio degradable polymer applied to the 
non-luminal surface of the stent. After implantation, the 
polymer is metab olised to water and carbon dioxide 
within 9 months.8,9 Biolimus is a highly lipophilic siro-
limus analogue that inhibits proliferation of smooth 
muscle cells.
A biodegradable polymer biolimus-eluting stent was 
assessed in the Limus Eluted from A Durable versus 
ERodable Stent coating (LEADERS) trial10,11 and was 
reported to be non-inferior to the durable polymer 
sirolimus-eluting Cypher stent (Cordis, Miami Lakes, FL, 
Lancet 2013; 381: 661–69
Published Online
January 30, 2013
http://dx.doi.org/10.1016/
S0140-6736(12)61962-X
This online publication has been 
corrected. The corrected version 
fi rst appeared at thelancet.com 
on July 26, 2013
See Comment page 609
Department of Cardiology, 
Aarhus University Hospital, 
Skejby, Aarhus, Denmark 
(E H Christiansen PhD, 
L R Krusell MD, A Kaltoft PhD, 
M Maeng PhD, 
Prof S D Kristensen DMSci, 
Prof H E Bøtker DMSci, 
C J Terkelsen DMSci, 
L Thuesen DMSci, 
J F Lassen PhD); Department of 
Cardiology, Odense University 
Hospital, Odense, Denmark 
(L O Jensen DMSci, 
P Thayssen DMSci, 
K N Hansen MD); Department 
of Cardiology, Aarhus 
University Hospital, Aalborg 
Hospital, Aalborg, Denmark 
(H-H Tilsted MD, 
A B Villadsen MD, 
J Ravkilde DMSci, J Aarøe MD); 
and Department of Clinical 
Epidemiology, Aarhus 
University Hospital, Aarhus, 
Denmark (M Madsen MSc)  
Correspondence to:
Dr Evald Høj Christiansen, 
Department of Cardiology, 
Aarhus University Hospital, 
Skejby, DK-8200, Denmark
evald.christiansen@dadlnet.dk
Articles
662 www.thelancet.com   Vol 381   February 23, 2013
USA) with respect to clinical safety and effi  cacy outcomes 
up until 4 years’ follow-up. The Intracoronary Stenting 
and Angiographic Results (ISAR-TEST 4) trial12 compared 
a biodegradable polymer stent (with a natural resin 
eluting sirolimus) with the durable polymer sirolimus-
eluting Cypher stent and reported no signifi cant 
diff erences in outcomes between the stents.12
The Scandinavian Organization for Randomized 
Trials with Clinical Outcome (SORT OUT) V trial aimed 
to further investigate the eff ects of a third-generation 
biodegradable biolimus-eluting stent compared with 
a fi rst-generation durable polymer-coated sirolimus-
eluting stent in a population-based setting, using registry 
detection of clinically driven events.13,14
Methods
Study design and patients
SORT OUT V is a randomised, multicentre, all-comer, 
two-arm, non-inferiority trial comparing a biolimus-
eluting stent with a sirolimus-eluting stent to treat 
coronary artery stenosis, undertaken at three hospitals 
across western Denmark. We used western Denmark 
registry data15,16 to compare randomised and non-
randomised patients during the study period so that we 
could assess how generalisable our study results would 
be (appendix).17 Eligible patients were aged 18 years or 
older, had chronic stable coronary artery disease or acute 
coronary syn dromes, and at least one coronary artery 
lesion with more than 50% diameter stenosis needing 
treatment with a DES. We did not place restrictions on 
the number of lesions or vessels to be treated, or lesion 
length. Exclusion criteria were life expectancy of less 
than 1 year; allergy to aspirin, clopidogrel, prasugrel, 
sirolimus, or biolimus; participation in another ran-
domised trial; clinical indications of an inability to 
tolerate dual antiplatelet treatment for 12 months; or 
inability to provide written informed consent.
The study complied with the Declaration of Helsinki 
and was approved by the Central Region Denmark ethics 
committee. All patients provided written informed 
consent for trial participation.
Randomisation
We enrolled patients and randomly allocated them to 
treatment groups after diagnostic coronary angiography 
and before percutaneous coronary intervention. Block 
randomisation by centre was used to assign patients 
(1:1) to receive a biolimus-eluting stent (Nobori, Terumo, 
Tokyo, Japan) or a sirolimus-eluting stent (Cypher Select 
Plus, Cordis, Johnson & Johnson, Warren, NJ, USA). 
The allocation sequence was computer-generated by an 
independent organisation, and was stratifi ed by sex, 
presence of diabetes, and presence of ST-segment 
elevation myocardial infarction. Patients were assigned 
to treatment through an automated telephone allo-
cation service. Although operators were not masked, 
all individuals analysing data were masked to treat-
ment assignment.
Procedures
The biolimus-eluting stent was available in three diam-
eters (2·50 mm, 3·00 mm, 3·50 mm) and fi ve lengths 
(8 mm, 14 mm, 18 mm, 24 mm, and 28 mm). The 
sirolimus-eluting stent was available in fi ve diameters 
(2·25 mm, 2·50 mm, 2·75 mm, 3·00 mm, and 
3·50 mm) and six lengths (8 mm, 13 mm, 18 mm, 
23 mm, 28 mm, and 33 mm). We implanted the stents 
according to standard techniques. We allowed direct 
stenting without previous balloon dilation. We 
attempted full lesion coverage by implantation of one or 
more stents. If several lesions needed to be treated in 
one patient, the allocated study stent had to be used in 
all lesions. However, we permitted the use of DES not 
specifi ed by the random allocation scheme, bare metal 
stents, and balloon angioplasty if the study stent could 
not be implanted.
Before implantation, patients received at least 75 mg of 
aspirin, a 600 mg loading dose of clopidogrel, and an 
unfractionated heparin dose (5000 IU or 70–100 IU/kg). 
Glycoprotein IIb/IIIa inhibitors were used at the 
operator’s discretion. Recommended postprocedure dual 
antiplatelet regi mens were 75 mg aspirin daily lifelong 
and clopidogrel 75 mg for 1 year. We also used prasugrel 
See Online for appendix
Figure 1: Trial profi le
*Not all eligible patients were included because some percutaneous coronary intervention operators at participating 
centres did not want the choice of stent to be decided by a randomisation process. 
7570 assessed for eligibility
1857 excluded
 1616 did not meet inclusion 
  criteria
 241 participated in other
  stent studies
3245 eligible, not included*
5713 eligible
2468 enrolled and randomised
1229 randomly assigned to biolimus-
 eluting stent (1532 lesions)
 1193 implanted with study stent
 36 not implanted with study stent 
1239 randomly assigned to sirolimus-
 eluting stent (1555 lesions)
 1208 implanted with study stent
 31 not implanted with study stent 
1228 completed 12 month clinical
 follow-up
1239 completed 12 month clinical
 follow-up
1229 analysed for primary endpoint 1239 analysed for primary endpoint
1 lost to follow-up 
 (emigration)
0 lost to follow-up
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treatment as an alternative to clopidogrel, with a loading 
dose of 60 mg and a daily dose of 10 mg.
The primary endpoint was a combination of safety 
(cardiac death, myocardial infarction, defi nite stent 
thrombosis) and effi  cacy (clinically indicated target vessel 
revascularisation) within 9 months of stent im plantation. 
We did intention-to-treat analyses after 9 months and 
again at 12 months after implantation. Secondary 
endpoints were: total mortality; cardiac mor tality; 
myocardial infarction; clinically indicated target lesion or 
vessel revascularisation; defi nite, probable, or possible 
stent thrombosis; and device delivery failure.
We defi ned cardiac death as any death due to an evident 
cardiac cause, any death related to percutaneous coronary 
intervention, unwitnessed death, or death from unknown 
causes. Myocardial infarction was de fi ned according to 
the universal defi nition used by the European Society of 
Cardiology, the American College of Cardiology, the 
American Heart Association, and the World Heart 
Federation.18 We did not assess biomarkers at the time of 
the index percutaneous coronary inter vention procedure. 
We classifi ed stent thrombosis as defi nite, probable, or 
possible stent thrombosis.19 We defi ned target vessel 
revascularisation as any repeat percutaneous coronary 
intervention or surgical bypass of any segment within 
the entire major coronary vessel that was proximal or 
distal to a target lesion, including upstream and 
downstream branches, and the target lesion itself. We 
defi ned target lesion revascularisation as repeat 
revascularisation caused by a more than 50% stenosis 
within the stent or within a 5 mm border proximal or 
distal to the stent. Device failure was defi ned as the 
inability to implant the assigned study stent in a target 
lesion. To establish comorbidity, we obtained data on 
hospital diagnoses for all patients from the Danish 
National Registry of Patients, covering all Danish 
hospitals from 1977 until the implantation date,20 and 
calculated each patient’s Charlson comorbidity index 
score, which covers 19 major disease categories, in-
cluding diabetes mellitus, heart failure, cerebrovascular 
diseases, and cancer.21
We used clinically driven event detection to avoid 
study-induced re-interventions. We obtained data on 
mortality, hospital admissions, coronary angiography, 
repeat percutaneous coronary intervention, and coronary 
bypass surgery for all randomly allocated patients from 
the following national Danish administrative and 
health-care registries: the Civil Registration System; the 
Western Denmark Heart Registry;15 the Danish National 
Registry of Patients20 (which maintains records for all 
hospital admissions in Denmark); and the Danish 
Registry of Causes of Death.22 An independent event 
committee, masked to treatment group assignment 
during the adjudication process, reviewed all endpoints 
and source documents to adjudicate causes of death, 
reasons for hospital admission, and diagnosis of myo-
cardial infarction. Two dedicated percutaneous coronary 
intervention operators at each participating centre 
reviewed cine fi lms for the event committee to classify 
stent thrombosis and target vessel revascularisation 
(either with percutaneous coronary intervention or 
coronary artery bypass grafting).
The Danish National Health Service provides universal 
tax-supported health care, guaranteeing residents free 
access to family doctors and hospitals. The Danish Civil 
Registration System, which is updated on a daily basis, 
has kept electronic records on sex, birth date, residence, 
Biolimus-eluting stent 
(n=1229)
Sirolimus-eluting stent 
(n=1239)
Age (years) 65·0 (10·6) 65·2 (10·3)
Men 917 (74·6%) 930 (75·1%)
Diabetes mellitus 185/1229 (15·1%) 189/1239 (15·3%)
Arterial hypertension 682/1180 (57·8%) 653/1189 (54·9%)
Hypercholesterolaemia 710/1179 (60·2%) 730/1190 (61·3%)
Current smoker 385/1145 (33·6%) 381/1152 (33·1%)
Body-mass index (kg/m²) 27·5 (5·2) 27·4 (5·2)
Previous myocardial infarction 209/1182 (17·7%) 206/1189 (17·3%)
Previous percutaneous coronary intervention 205/1182 (17·3%) 196/1191 (16·5%)
Previous coronary artery bypass grafting 96/1184 (8·1%) 71/1195 (5·9%)
Indication for percutaneous coronary intervention
ST-segment elevation MI 225 (18·3%) 227 (18·3%)
Non-ST-segment elevation MI or unstable angina 372 (30·3%) 384 (31·0%)
Stable angina 608 (49·5%) 596 (48·1%)
Other 24 (2·0%) 32 (2·6%)
Number of lesions
1 903 (73·5%) 925 (74·7%)
2 253 (20·6%) 244 (19·7%)
3 61 (5·0%) 59 (4·8%)
>3 12 (1·0%) 11 (0·9%)
Number of lesions per patient 1·25 (0·6) 1·26 (0·6)
Target vessel location
Left main artery 21 (1·4%) 21 (1·4%)
Left anterior descending artery 623 (40·7%) 636 (40·9%)
Left circumfl ex artery 355 (23·2%) 350 (22·5%)
Right artery 508 (33·2%) 535 (34·4%)
Saphenous vein graft 25 (1·6%) 13 (0·8%)
Lesion type
A 200 (13·1%) 225 (14·5%)
B1 478 (31·2%) 512 (32·9%)
B2 262 (17·1%) 242 (15·6%)
C 592 (38·6%) 576 (37·0%)
Chronic total occlusion lesions 90 (6·0%) 109 (7·2%)
Bifurcation lesions 225 (15·0%) 229 (15·1%)
Lesion length >18 mm 521 (34·1%) 522 (33·6%)
Lesion length (mm) 18·0 (12·0–27·0) 18·0 (11·0–29·0)
Reference vessel size (mm) 3·2 (3·0–3·5) 3·3 (3·0–3·6)
Data are mean (SD), number (%), or median (IQR). Previous percutaneous coronary intervention and reference 
vessel size diff ered signifi cantly between groups at baseline (p=0·039 and p=0·031, respectively). Some of the 
1229 participants’ data is missing for some variables because it was not recorded in the Western Denmark Heart 
Registry. MI=myocardial infarction.
Table 1: Baseline characteristics of the study population
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emigration date, and vital status changes since 1968;20 the 
ten-digit civil registration number assigned at birth and 
used in all registries allows accurate record linkage. The 
Civil Registration System provided vital status data for 
our study participants and minimised loss to follow-up. 
The National Registry of Causes of Deaths and the 
Danish National Registry of Patients provided infor-
mation on causes of death and diagnoses made during 
hospital admissions (coded according to the International 
Classifi cation of Diseases, 10th revision).22
Statistical analysis
The trial was powered for assessing non-inferiority of the 
biolimus-eluting stent compared with the sirolimus-
eluting stent with respect to the primary endpoint at 
9 months. On the basis of results from the SORT OUT III 
trial,13 we assumed an event rate of 3% in the sirolimus-
eluting stent group. No valid estimate for event rate in an 
all-comer population after treatment with the biolimus-
eluting Nobori stent was available. With a sample size of 
1200 patients in each treatment group, a two-group large-
sample normal approximation test of proportions with a 
one-sided 0·05 signifi cance level would have 90% power 
to detect non-inferiority with a predetermined non-
inferiority margin of 0·02. The sample size of 1200 in 
each group assumes 0% of patients are lost to follow-up, 
since we used the Civil Registration System. 
A Farrington-Manning test was used to test for non-
inferiority. We compared distri butions of continuous 
variables between study groups using the two-sample 
t test (or Cochran test for cases of unequal variance) or 
the Mann-Whitney U test, depending on whether the 
data followed a normal distribution. We analysed distri-
butions of categorical variables using the χ² test. In 
analyses of every endpoint, follow-up continued until 
the date of an endpoint event, death, emigration, or 
12 months after stent implantation, whichever came fi rst. 
We constructed survival curves based on time to events, 
accounting for the competing risk of death.23 Patients 
who received the sirolimus-eluting stent were used as the 
reference group for overall and subgroup analyses. We 
calculated risk diff erences for major adverse cardiac 
events at 12 month follow-up for prespecifi ed patient 
subgroups (based on baseline demographic and clinical 
characteristics). The intention-to-treat principle was used 
in all analyses. Except for the inferiority testing of the 
primary endpoint, we regarded a two-sided p value of less 
than 0·05 to indicate statistical signifi cance. We used 
Cox proportional hazards regres sion analysis to assess 
whether diff erence detected at baseline had any eff ect 
on the result. We did analyses using SAS software 
(version 9.2). This trial is registered with ClinicalTrials.
gov, number NCT01254981.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. They also did not have access to the 
clinical trial database, nor any opportunity to review the 
manuscript. The corresponding author had full access to 
all the data in the study and fi nal responsibility for the 
decision to submit for publication.
Results
Between July, 2009, to January, 2011, we screened 
7570 patients and randomly assigned 2468 patients with 
3087 lesions to receive either the biolimus-eluting stent 
(1229 patients with 1532 lesions) or the sirolimus-eluting 
stent (1239 patients with 1555 lesions; fi gure 1). 3245 eligible 
patients were not enrolled, mainly because some operators 
at the participating centres preferred not to leave stent 
selection to a randomised process. One patient was lost to 
follow-up on day 112 because of emigration.
Baseline demographic and clinical characteristics in 
the two study groups were well balanced except for a 
slightly higher rate of previous coronary artery bypass 
grafting in the biolimus-eluting stent group (table 1). A 
high proportion of patients in both groups had acute 
coronary syndromes, multivessel disease, and complex 
lesions (table 1). Diabetes was equally distributed and 
reported in 15% of patients. Apart from a higher maxi-
mum stent implantation pressure (table 2) and larger 
reference vessel diam eter in the sirolimus-eluting group, 
procedure results (such as the rate of device delivery 
failure and indices of procedure duration, fl uoroscopy 
time, and use of contrast) and lesion characteristics were 
similar in the study groups (table 2).
The 9 month composite primary endpoint occurred in 
50 (4·1%) of 1229 patients in the biolimus-eluting stent 
group and in 39 (3·1%) of 1239 patients in the sirolimus-
eluting stent group (fi gure 2). With an absolute risk 
diff erence of 0·9% and the upper limit of the one-
sided 95% CI at 2·1% (one-sided pnon-inferiority=0·06), 
Biolimus-eluting 
stent (n=1229)
Sirolimus-eluting 
stent (n=1239)
p value
More than one stent
Per patient 448 (36·5%) 450 (36·3%) 0·56
Per lesion 279 (18·3%) 300 (19·2%) 0·79
Total stent length (mm)
Per patient 22·0 (14·0–32·0) 23·0 (13·0–33·0) 0·22
Per lesion 15·0 (10·0–20·0) 15·0 (10·0–20·0) 0·51
Direct stenting 329 (21·6%) 345 (22·4%) 0·60
Stent delivery failure 26 (1·7%) 31 (2·0%) 0·54
Maximum pressure (atm) 16·0 (14·0–20·0) 18·0 (15·0–20·0) <0·0001
Length of procedure (min) 24·0 (16·0–38·0) 24·0 (15·0–38·0) 0·94
Fluoroscopy time (min) 6·5 (4·0–12·0) 6·9 (4·0–12·2) 0·27
Contrast (mL) 100·0 (60·0–130·0) 100·0 (60·0–140·0) 0·64
Use of glycoprotein IIb/IIIa inhibitors 195 (15·9%) 209 (16·9%) 0·50
Data are number (%) or median (IQR).
Table 2: Procedure characteristics 
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non-inferiority of the biolimus-eluting stent versus the 
sirolimus-eluting stent was not shown. Rates of death, 
cardiac death, myocardial infarction, and clinically 
driven target vessel revascularisation at 9 months did 
not diff er signifi cantly between the two stent groups 
(table 3). The result was similar for the composite 
endpoint at 12 months, which occurred in 66 (5·4%) 
patients in the biolimus-eluting stent group and in 
55 (4·4%) patients in the sirolimus-eluting stent group 
(table 3 and fi gure 2). Defi nite stent thrombosis occurred 
within 12 months in nine (0·7%) patients in the 
biolimus-eluting stent group and in two (0·2%) patients 
in the sirolimus-eluting stent group (p=0·034). We did 
not detect late defi nite stent thrombosis in any patient. 
At 12 month follow-up, defi nite or probable stent 
thrombosis did not diff er between the two groups 
(table 3). Clinically driven target lesion revascularisation 
occurred within 9 months in 30 (2·4%) patients in the 
Figure 2: Time-to-event curves for major adverse cardiac events
*Cardiac death, myocardial infarction, defi nite stent thrombosis, and target vessel revascularisation.
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biolimus-eluting stent group and 16 (1·3%) patients in 
the sirolimus-eluting stent group (p=0·035).
Findings for the primary endpoint were consistent 
across prespecifi ed subgroups (fi gure 3). Specifi cally, the 
primary endpoint did not diff er signifi cantly between the 
two stent groups in patients with and without diabetes 
mellitus. Due to the small imbalance in proportion of 
patients with previous coronary artery bypass graft and 
diff erence in reference vessel diameter between groups, 
we adjusted for these variables with Cox proportional 
hazards regression analysis. This did not change the 
results (data not shown).
Results of per-protocol analysis showed that 45 (3·8%) 
of 1193 patients who received a biolimus-eluting stent 
and 39 (3·2%) of 1208 patients who received the 
sirolimus-eluting stent met the primary endpoint (risk 
diff erence 0·5% [upper limit of one-sided 95% CI 1·8%]; 
pnon-inferiority=0·03). 
Discussion
Our SORT OUT V trial is the largest head-to-
head comparison of the biodegradable polymer-coated 
biolimus-eluting Nobori stent and the permanent 
polymer-coated sirolimus-eluting Cypher stent.9 At 9 and 
12 month assessment of clinical safety and effi  cacy, the 
results of the study did not show non-inferiority of the 
biolimus-eluting stent compared with the sirolimus-
eluting stent.
This result contrasts with that of the LEADERS trial, 
which also compared a biolimus-eluting biodegradable 
polymer-coated stent with the sirolimus-eluting Cypher 
stent.10 The biodegradable stent of the LEADERS trial 
(BioMatrix Flex, Biosensors, Newport Beach, CA, USA) is 
almost identical to the Nobori stent used in our study. The 
stent platforms are made of the same stainless steel alloy 
and the biodegradable polymer is the same. However, the 
Nobori stent has an ultra-thin non-degradable parylene 
coating between the stent and the biodegradable polymer 
to assure polymer attachment to the stent struts.
In the LEADERS trial, the event rate for the primary 
endpoint for both stents was almost twice as high as in 
SORT OUT V, and the investigators concluded that the 
biodegradable polymer study stent was non-inferior to the 
sirolimus-eluting stent.10 By contrast with the LEADERS 
trial, we did not routinely assess pro cedural biomarkers, 
and did not record asymptomatic and electrocardiograph 
silent procedure-related myo cardial damage. The higher 
rate of new revascularisations in the LEADERS trial (4·4% 
with the biolimus-eluting stent vs 5·5% with the sirolimus-
eluting stent) compared with our trial (3·3% vs 2·1%) 
might be explained by the fact that 25% of patients in the 
LEADERS trial had a prescheduled angiography follow-
up.24 Further more, the rate of diabetes was twice as high in 
the LEADERS trial as in our trial in which 15% of patients 
had diabetes, a rate that is characteristic for interventional 
studies in Nordic countries.
We cannot explain why, in our trial, the 12 month 
event rates in the biolimus-eluting stent group were 
higher than those in the sirolimus-eluting stent group. 
Although non-signifi cant, the diff erence was noted in 
all elements of the combined endpoint and across 
patient subgroups. The diff erences seemed to occur 
mainly during the fi rst month and were most pro-
nounced in the endpoints of stent thrombosis, myo-
cardial infarction, and new revascularisations (fi gure 2). 
We cannot exclude that the non-degradable parylene 
coating between the stent and the biodegradable 
polymer, covering the entire stent, might be a causal 
factor. Other explanations might be the signifi cant, but 
small, diff erence in implantation pressures between the 
two groups, with a possibly improved apposition 
Biolimus-
eluting stent 
(n=1229)
Sirolimus-
eluting stent 
(n=1239)
Risk diff erence 
(95% CI)
p value
Events at 30 days
All-cause mortality 8 (0·7%) 7 (0·6%) 0·1% (−0·5 to 0·7) 0·78
Cardiac death 6 (0·5%) 6 (0·5%) 0·0% (−0·5 to 0·6) 0·99
Myocardial infarction 10 (0·8%) 3 (0·2%) 0·6% (0·0 to 1·1) 0·050
Target vessel revascularisation 14 (1·1%) 8 (0·6%) 0·5% (−0·2 to 1·2) 0·19
Target lesion revascularisation 11 (0·9%) 7 (0·6%) 0·3% (−0·3 to 1·0) 0·34
Defi nite stent thrombosis 9 (0·7%) 2 (0·2%) 0·6% (0·0 to 1·1) 0·034
Events at 9 months
Composite primary endpoint* 50 (4·1%) 39 (3·1%) 0·9% (−0·6 to 2·4) 0·22
All-cause mortality 22 (1·8%) 22 (1·8%) 0·0% (−1·0 to 1·1) 0·98
Cardiac death 8 (0·7%) 12 (1·0%) −0·3% (−1·0 to 0·4) 0·38
Myocardial infarction 16 (1·3%) 8 (0·6%) 0·7% (−0·1 to 1·4) 0·097
Defi nite stent thrombosis† 9 (0·7%) 2 (0·2%) 0·6% (0·0 to 1·1) 0·034
Target vessel revascularisation 40 (3·3%) 26 (2·1%) 1·2% (−0·1 to 2·4) 0·075
Target lesion revascularisation 30 (2·4%) 16 (1·3%) 1·1% (0·1 to 2·2) 0·035
Events at 12 months
Composite endpoint* 66 (5·4%) 55 (4·4%) 0·9% (−0·8 to 2·6) 0·28
All-cause mortality 30 (2·4%) 27 (2·2%) 0·3% (−0·9 to 1·4) 0·67
Cardiac death 12 (1·0%) 14 (1·1%) −0·2% (−1·0 to 0·7) 0·71
Composite endpoint based on all-cause 
mortality†
82 (6·7%) 68 (5·5%) 1·2% (−0·7 to 3·1) 0·22
Myocardial infarction 19 (1·5%) 11 (0·9%) 0·7% (−0·2 to 1·5) 0·14
Stent thrombosis‡
Defi nite 9 (0·7%) 2 (0·2%) 0·6% (0·0 to 1·1) 0·034
Acute (<24 h) 5 (0·4%) 1 (0·1%) 0·3% (−0·1 to 0·7) 0·10
Subacute (24 h to 30 days) 4 (0·3%) 1 (0·1%) 0·2% (−0·1 to 0·6) 0·18
Late (31 days to 12 months) 0 0 NA NA
Probable 1 (0·1%) 2 (0·2%) −0·1% (−0·4 to 0·2) 0·57
Defi nite or probable 10 (0·8%) 4 (0·3%) 0·5% (−0·1 to 1·1) 0·11
Possible 3 (0·2%) 5 (0·4%) −0·2% (−0·6 to 0·3) 0·75
Target vessel revascularisation 52 (4·2%) 39 (3·1%) 1·1% (−0·4 to 2·6) 0·15
Target lesion revascularisation 40 (3·3%) 25 (2·0%) 1·2% (0·0 to 2·5) 0·055
Data are number (%) unless otherwise indicated. Two-sided CIs have been used for all endpoints. *Cardiac death, 
myocardial infarction, defi nite stent thrombosis, and clinically-driven target vessel revascularisation. †All-cause 
mortality, myocardial infarction, defi nite stent thrombosis, and clinically-driven target vessel revascularisation. 
‡Academic Research Consortium defi nition. 
Table 3: Clinical outcomes
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between stent struts and vessel wall in the patients who 
received the sirolimus-eluting stent.
The SORT OUT IV study documented similar safety 
and effi  cacy between the sirolimus-eluting Cypher stent 
and the second-generation everolimus-eluting Xience V 
stent.14 The COMPARE II trial randomly assigned 
2707 patients (2:1) to the biolimus-eluting Nobori stent or 
an everolimus-eluting stent (Xience V or Prime, Abbott 
Vascular, Santa Clara, CA, USA, or Promus, Boston 
Scientifi c, Natick, MA, USA; panel).25 Although the 
event rates in the biolimus-eluting stent group were 
numerically higher than in the everolimus-eluting stent 
group, the study showed non-inferiority of the biolimus-
eluting stent. At 12 months, rates of major cardiac events 
at 12 months were 5·2% with the biolimus-eluting stent 
versus 4·8% with the everolimus-eluting stent and the 
rates of defi nite stent thrombosis were 0·7% versus 
0·4%. These results are similar to those reported in our 
study (5·4% with the biolimus-eluting stent vs 4·4% with 
the sirolimus-eluting stent for major cardiac events and 
0·7% vs 0·2% for defi nite stent thrombosis), so despite 
our study not showing non-inferiority, our results are 
backed up by 12 month safety and effi  cacy data from 
COMPARE II, which also compared an older-generation 
DES with the biolimus-eluting Nobori stent.
Very late stent thrombosis (generally defi ned as 
occur ring >1 year after implantation) has been a weak-
ness of fi rst-generation DES. Therefore, our follow-up 
Figure 3: Prespecifi ed subgroup analysis for the composite endpoint* at 12 months 
Data are number of events (% of patients). Major adverse cardiac events are a composite of cardiac death, myocardial infarction, defi nite stent thrombosis, and 
target vessel revascularization. LAD=left anterior descending artery. MI=myocardial infarction. PCI=percutaneous coronary intervention. STEMI=ST-elevation 
myocardial infarction. *Cardiac death, myocardial infarction, defi nite stent thrombosis, and clinically indicated target vessel revascularisation.
Events (% of patients) Risk difference 
(95% CI)
pinteraction
Biolimus-
eluting stent
Sirolimus-
eluting stent
No acute coronary syndrome
Acute coronary syndrome
Age ≤65 years
Age >65 years
No diabetes
Diabetes
No stenosis in LAD
Stenosis in LAD
Lesion type C
Not lesion type C
Female
Male
No multivessel disease
Multivessel disease
>1 stent/patient
1 stent/patient
No previous MI
Previous MI
No previous PCI
Previous PCI
Reference segment ≥2·75 mm
Reference segment <2·75 mm
No STEMI
STEMI
All groups
36 (5·7%)
30 (5·0%)
28 (4·4%)
38 (6·4%)
54 (5·2%)
12 (6·5%)
37 (5·6%)
29 (5·1%)
29 (5·5%)
37 (5·3%)
21 (6·7%)
45 (4·9%)
53 (5·2%)
13 (6·4%)
13 (6·4%)
53 (5·2%)
53 (5·4%)
11 (5·3%)
49 (5·0%)
15 (7·3%)
46 (5·1%)
20 (6·2%)
52 (5·2%)
14 (6·2%)
66 (5·4%)
30 (4·8%)
25 (4·1%)
20 (3·2%)
35 (5·7%)
40 (3·8%)
15 (7·9%)
27 (4·2%)
28 (4·7%)
29 (5·5%)
26 (3·7%)
16 (5·2%)
39 (4·2%)
44 (4·3%)
11 (5·0%)
11 (5·0%)
44 (4·3%)
41 (4·2%)
11 (5·3%)
42 (4·2%)
12 (6·1%)
45 (4·6%)
10 (3·8%)
41 (4·1%)
14 (6·2%)
55 (4·4%)
 0·94
 
 0·55
 
 0·24
 
 0·53
 
 0·29
 
 0·78
 
 0·86
 
 0·86
 
 0·54
 
 0·98
 
 0·37
 
 0·58
 ··
Favours biolimus-eluting stent Favours sirolimus-eluting stent
Percent
0–1 1–2–3–4–5–6–7 2 3 4 5 6
 0·9% (–1·5 to 3·4)
 0·9% (–1·4 to 3·3)
 1·2% (–0·9 to 3·3)
 0·6% (–2·1 to 3·3)
 1·4% (–0·4 to 3·1)
 –1·5% (–6·7 to 3·8)
 1·4% (–0·9 to 3·8)
 0·4% (–2·1 to 2·8)
 0·0% (–2·8 to 2·7)
 1·6% (–0·5 to 3·8)
 1·6% (–2·2 to 5·3)
 0·7% (–1·2 to 2·6)
 0·8% (–1·0 to 2·7)
 1·4% (–3·0 to 5·9)
 1·4% (–3·0 to 5·9)
 0·8% (–1·0 to 2·7)
 1·3% (–0·6 to 3·2)
 –0·1% (–4·4 to 4·2)
 0·8% (–1·1 to 2·6)
 1·2% (–3·7 to 6·1)
 0·5% (–1·5 to 2·4)
 2·4% (–1·1 to 5·8)
 1·1% (–0·7 to 3·0)
 0·1% (–4·4 to 4·5)
 0·9% (–0·8 to 2·6)
Panel: Research in context
Systematic review
We searched PubMed, EuroPCR, and Transcatheter Cardiovascular Therapeutics (TCT) 
conferences for reports on randomised trials comparing the biolimus-eluting biodegradable 
polymer-coated Nobori stent with durable polymer stents powered for clinical endpoints 
with the search terms “Nobori”, “stent”,  “randomised”, or “randomized”, published 
between Jan 1, 2003, and June 1, 2012.  We identifi ed the COMPARE II trial,25 which 
randomly assigned (2:1) 2707 patients to the biolimus-eluting Nobori stent or an 
everolimus-eluting stent. At 12 months, the rates of major adverse cardiac events and 
defi nite stent thrombosis were higher in the biolimus-eluting stent group than in the 
everolimus-eluting stent group, but using a non-inferiority margin of 4%, the investigators 
concluded non-inferiority of the biolimus-eluting stent. We identifi ed additional reports 
cited in this Article by searching PubMed with the term “biolimus-eluting stent”.
Interpretation
Our study and the COMPARE II trial show that at 1 year, the biodegradable polymer 
biolimus-eluting Nobori stent does not improve clinical results compared with the 
fi rst-generation sirolimus-eluting or everolimus-eluting durable polymer stents. 
However, long-term data will be needed before we can make recommendations for 
the role of the Nobori stent in routine clinical practice.
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